Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR3 | P25089 | 1/20 | 0.39 |
| ▸ | FPR2 | P25090 | 1/20 | 0.39 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.37 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.37 |
| ▸ | CNR1 | P21554 | 3/20 | 0.35 |
| ▸ | CNR2 | P34972 | 4/20 | 0.34 |
| ▸ | MME | P08473 | 4/20 | 0.33 |
| ▸ | AURKA | O14965 | 1/20 | 0.33 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.33 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1153869 | 0.93 | FPR3 (0.38) | FPR3FPR2TAS1R3TAS1R1CNR1 | |
| SCHEMBL1153044 | 0.93 | FPR3 (0.38) | FPR3FPR2TAS1R3TAS1R1CNR1 | |
| SCHEMBL1152945 | 0.91 | FPR3 (0.37) | FPR3FPR2TAS1R3TAS1R1CNR1 | |
| SCHEMBL3541461 | 0.91 | FPR3 (0.37) | FPR3FPR2TAS1R3TAS1R1CNR1 | |
| SCHEMBL6016728 | 0.88 | FPR3 (0.34) | FPR3FPR2TAS1R3TAS1R1CNR1 | |
| SCHEMBL1153446 | 0.76 | MME (0.33) | CNR1CNR2MMEALDH1A1 | |
| SCHEMBL4341862 | 0.76 | TAS1R3 (0.42) | TAS1R3TAS1R1CNR1CNR2MME | |
| SCHEMBL25291547 | 0.74 | ALDH1A1 (0.42) | TAS1R3TAS1R1CNR1MMEAURKA | |
| SCHEMBL11073459 | 0.74 | ALDH1A1 (0.52) | TAS1R3TAS1R1CNR1CNR2MME | |
| SCHEMBL3306198 | 0.74 | ALDH1A1 (0.42) | TAS1R3TAS1R1CNR1MMEAURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7943799-B2 | Method for producing optically active cycloalkylidenebisoxazoline compound and intermediate thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-05-17 | — | — | US | disclosed |
| US-20110046415-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE CYCLOALKYLIDENEBISOXAZOLINE COMPOUND AND INTERMEDIATE THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-02-24 | — | — | US | disclosed |
| US-7842839-B2 | Method for producing optically active cycloalkylidenebisoxazoline compound and intermediate thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-11-30 | — | — | US | disclosed |
| US-20070112201-A1 | Method for producing optically active cycloalkylidenebisoxazoline compound and intermediate thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2007-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070112201-A1 | Method for producing optically active cycloalkylidenebisoxazoline compound and intermediate thereof | CYP3A7, GRK7, CYP2A7 | FPR3 546/4885FPR2 1020/4885TAS1R3 3434/4885 |
| US-20110046415-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE CYCLOALKYLIDENEBISOXAZOLINE COMPOUND AND INTERMEDIATE THEREOF | CYP3A7, GRK7, CYP2A7 | FPR3 546/4885FPR2 1020/4885TAS1R3 3434/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.